HC Wainwright & Co. Reiterates Buy on Fate Therapeutics, Maintains $7 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 92.4%

Neg 0% Neu 92.4% Pos 0%

HC Wainwright & Co. analyst Robert Burns reiterates Fate Therapeutics (NASDAQ:FATE) with a Buy and maintains $7 price target.